These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Acylated plasminogen-streptokinase activator complex: a new approach to thrombolytic therapy. Crabbe SJ; Grimm AM; Hopkins LE Pharmacotherapy; 1990; 10(2):115-26. PubMed ID: 2140889 [TBL] [Abstract][Full Text] [Related]
7. Tolerance and complications in a multicenter trial of intravenous APSAC and intracoronary streptokinase in acute myocardial infarction. Rothbard RL; Anderson JL; Fitzpatrick PG; Hakworthy RA; Sorensen SG; Marder VJ Clin Cardiol; 1990 Mar; Suppl 5():V11-4; discussion V27-32. PubMed ID: 2182234 [TBL] [Abstract][Full Text] [Related]
8. Safety and tolerance data from the Belgian multicentre study of anisoylated plasminogen streptokinase activator complex versus heparin in acute myocardial infarction. Bossaert LL Drugs; 1987; 33 Suppl 3():287-92. PubMed ID: 3315610 [TBL] [Abstract][Full Text] [Related]
9. Systemic effects of anisoylated plasminogen streptokinase activator complex and streptokinase therapy in acute myocardial infarction. Coagulation aspects of the Dutch Invasive Reperfusion Study. Hoffmann JJ; Bonnier JJ; de Swart JB; Custers P; Vijgen M Drugs; 1987; 33 Suppl 3():242-6. PubMed ID: 3315602 [TBL] [Abstract][Full Text] [Related]
10. Preliminary safety and tolerance data obtained in the comparative study of anisoylated plasminogen streptokinase activator complex versus heparin. Croydon EA Drugs; 1987; 33 Suppl 3():293-6. PubMed ID: 3315611 [TBL] [Abstract][Full Text] [Related]
11. Safety and side effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study. Monassier JP; Hanssen M Drugs; 1987; 33 Suppl 3():282-5. PubMed ID: 3315608 [TBL] [Abstract][Full Text] [Related]
12. Anisoylated plasminogen streptokinase activator complex versus placebo. A preliminary multicentre study of safety and early mortality in acute myocardial infarction. Julian DG; Borthwick LS; Reid D; Jennings KP; Wainwright RJ; Rodger JC; Wood D; Phillips WS Drugs; 1987; 33 Suppl 3():261-7. PubMed ID: 3315604 [TBL] [Abstract][Full Text] [Related]
13. Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study. Monassier JP; Hanssen M Drugs; 1987; 33 Suppl 3():247-52. PubMed ID: 2445540 [TBL] [Abstract][Full Text] [Related]
14. Acyl-enzymes as thrombolytic agents in dog models of venous thrombosis and pulmonary embolism. Dupe RJ; English PD; Smith RA; Green J Thromb Haemost; 1984 Apr; 51(2):248-53. PubMed ID: 6234676 [TBL] [Abstract][Full Text] [Related]
15. On the fibrinolytic and thrombolytic properties of active-site p-anisoylated streptokinase-plasminogen complex (BRL 26921). Matsuo O; Collen D; Verstraete M Thromb Res; 1981 Nov; 24(4):347-58. PubMed ID: 7038976 [No Abstract] [Full Text] [Related]
16. Comparative tolerance and complications in a multicentre trial of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. Rothbard RL Drugs; 1987; 33 Suppl 3():276-8. PubMed ID: 3315606 [TBL] [Abstract][Full Text] [Related]
17. Initial experience with a new fibrinolytic agent (APSAC) in patients with major pulmonary embolism. Bett JH; Bunce IH; Cade JF; Concannon AJ; Gallus A; Low J Aust N Z J Med; 1987 Feb; 17(1):77-9. PubMed ID: 3304242 [No Abstract] [Full Text] [Related]